Impaired liver function: effect on paclitaxel toxicity, dose modifications and overall survival
This study revealed that patients with impaired liver function treated with paclitaxel for breast and ovarian cancer in an advanced setting are at greater risk of developing hematological toxicity than patients with normal liver function at the start of therapy. Furthermore, in patients with ovarian (advanced) or inoperable esophageal cancer, impaired liver function is associated with decreased OS. Within these groups of patients, it is important to weigh the risk of upfront paclitaxel dose modifications versus an adaptive strategy.
Authors
- Laureen A. Lammers (ORCID: https://orcid.org/0000-0001-9986-0542)
- Merel van Nuland (ORCID: https://orcid.org/0000-0003-1763-7334)
- Saskia Haitjema (ORCID: https://orcid.org/0000-0001-5465-4868)
- Toine C. G. Egberts (ORCID: https://orcid.org/0000-0003-1758-7779)
- Robin W.M. Vernooij (ORCID: https://orcid.org/0000-0001-5734-4566)
- Erin H. Smeijsters (ORCID: https://orcid.org/0000-0002-5264-5228)
- Lot A. Devriese (ORCID: https://orcid.org/0009-0009-9324-7814)
- Nadia Haj Mohammad (ORCID: https://orcid.org/0000-0002-4688-2921)
- Thom Hermens
- Marieke Schmidt
- J Stammers
- Christina Swart
Institutions
- Utrecht University (NL)
- University Medical Center Utrecht (NL)
Publication Details
- Journal
- BMC Cancer
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1186/s12885-024-13330-2
- Citations
- 6
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 1.70